Highlight Capital — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Verseau Therapeuticsverseautx.cominMar 2017
Verseau Therapeutics discovers and develops macrophage-targeting monoclonal antibodies to enhance anti-tumor immune responses in cancer patients.
AI & Machine LearningBiotechHealthtechMedical DevicesAuburndale, US
Bob Langer(Director, Promoter)Dan Anderson(Executive Officer, Director, Promoter)inTatiana NovobrantsevainIgor FeldmaninWalter Capone(Executive Officer)Christine Bunt(Executive Officer, Director)in
Co-investors20/20 HealthCare Partners LLC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.